

**Table S13: Subgroup analysis in the per-protocol population: Incidence rate ratios WGF versus CF (95% CI) with p-values for intervention effect between subgroups**

SUBGROUP		AD <sub>PRIMARY</sub> <sup>a</sup>		AD <sub>UKWP</sub> <sup>a</sup>		AD <sub>DOCTOR</sub> <sup>a</sup>		AD <sub>ANY</sub> <sup>a</sup>	
		IRR (95% CI)	p-value <sup>b</sup>	IRR (95% CI)	p-value <sup>b</sup>	IRR (95% CI)	p-value <sup>b</sup>	IRR (95% CI)	p-value <sup>b</sup>
Country			0.96		0.86		0.42		0.28
	ES	0.96 (0.65–1.43)		0.89 (0.61–1.31)		0.63 (0.45–0.89)**		0.69 (0.51–0.93)*	
	PL	0.95 (0.54–1.67)		0.95 (0.54–1.65)		0.9 (0.41–1.97)		0.96 (0.57–1.63)	
Age at enrolment			0.071		0.084		0.86		0.76
	≥ 4 weeks	0.62 (0.34–1.11)		0.6 (0.34–1.07)		0.7 (0.38–1.29)		0.7 (0.44–1.13)	
	< 4 weeks	1.18 (0.79–1.75)		1.1 (0.75–1.61)		0.66 (0.46–0.94)*		0.77 (0.56–1.05)	
Parental AD			<b>0.002</b>		<b>0.003</b>		<b>0.01</b>		<b>0.004</b>
	No	1.19 (0.83–1.7)		1.1 (0.78–1.55)		0.78 (0.56–1.08)		0.86 (0.65–1.14)	
	Yes	0.24 (0.08–0.69)**		0.24 (0.08–0.71)**		0.21 (0.07–0.62)**		0.25 (0.1–0.61)**	
Sex			0.54		0.65		0.55		0.26
	Male	1.03 (0.69–1.55)		0.96 (0.65–1.43)		0.72 (0.48–1.08)		0.85 (0.6–1.19)	
	Female	0.84 (0.48–1.45)		0.82 (0.49–1.39)		0.6 (0.37–0.97)*		0.63 (0.41–0.94)*	

<sup>a</sup>n=1441; <sup>b</sup>p-values for interaction: : adjusted estimates including gender and country as covariates, center as a random effect, and an offset for observation time. The different effect of intervention between subgroups was assessed using a likelihood-ratio test; \*p<0.05; \*\*p<0.01

WGF: Whole goat milk formula; CF: Cow milk formula; AD: Atopic dermatitis; ES: Spain; PL: Poland; UKWP: United Kingdom Working Party; IRR: Incidence rate ratio; CI: confidence interval